ABSTRACT Targeted and immunotherapy have revolutionized cancer treatment. They safely substitute for traditional chemotherapy in a significant and growing number of malignancies. In this article, we review the United States Food and Drug Administration (FDA) - approved targeted and immunotherapies, currently used in oncology and compare their safety and efficacy...
ABSTRACT Objectives: Osimertinib is a third-generation EGFR inhibitor with activity against both sensitizing and resistance mutations. Following results of the phase III study, AURA3, which led to the approval of osimertinib worldwide, we have conducted ASTRIS with the aim of confirming the efficacy and safety of osimertinib. Methods: This is a phase...
